Kupando

Germany
Schönefeld, Brandenburg, Germany, 12529

Company profile

Kupando company profile

KUPANDO is a pioneering biopharmaceutical firm that is developing TLR 4/7 agonists to boost innate immunity. The company's mission is to provide cancer patients with not only safe but also inexpensive immunotherapy, as well as to produce immunostimulatory drugs capable of preventing infectious illnesses.

Business identity

Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2018-01-01, Year

Headquarters

Postal code
12529
Country code
DE
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
1
Total equity funding
$12.5M
Last funding
Series A / $12.5M / 2022-09-26
Last equity funding
Series A / $12.5M
Investors
5
Lead investors
2
Founders
1
Articles
2

Founders and investors

Founders

Johanna Holldack

Lead investors

LifeCare PartnersRemiges Ventures

Investors

Brandenburg KapitalHTGF (High-Tech Gruenderfonds)LifeCare PartnersRemiges VenturesVentura BioMed Investors